Press Releases

18/05 Terumo : Q&A Session at the Financial Results for the Fiscal Year Ended March 31, 2026 PU
18/05 Terumo : Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)(with note) PU
15/05 Terumo : GS26 Final Year and Beyond & Terumo Neuro Growth Roadmap PU
15/05 Terumo : Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025) PU
15/05 Terumo : IFRS Financial Results for the Fiscal Year Ended March 31, 2026 PU
15/05 Terumo : Announces Candidates for Directors PU
14/05 OrganOx Announces Appointment of Naoya Iwata as CEO & President AQ
30/04 Terumo : Issued its First U.S. Dollar-Denominated Senior Unsecured Notes PU
15/04 Terumo Corporation Joins the Healthcare Plastics Recycling Council AQ
19/02 Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships AQ
16/02 Terumo : Q&A Session at the Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 PU
16/02 Terumo : Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 (FY2025)(with note) PU
13/02 Terumo : Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 (FY2025) PU
13/02 Terumo : IFRS Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 PU
16/01 Terumo : J.P. Morgan Healthcare Conference 2026 PU
14/01 PRESSWIRE 2023: Diabeloop and Sequel Med Tech Enter Partnership to Integrate FDA-Cleared DBLG2 into the twiistâ„¢ Automated Insulin Delivery System AQ
13/01 Terumo : 44th J.P.Morgan Healthcare Conference PU
13/11 Terumo : Q&A Session at the Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 PU
13/11 Terumo : Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 (FY2025)(with note) PU
12/11 Terumo : Notice Concerning Revisions to Full-Year Financial Guidance for Fiscal Year Ending March 31, 2026 (FY2025) PU
12/11 Terumo : IFRS Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 PU
12/11 TIS Growth Roadmap: Advancing Terumo’s Core Business through the Launch of DSS PU
12/11 Terumo : Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2026 (FY2025) PU
30/25/30 OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation AQ
28/25/28 Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements AQ
No results for this search